BioSyent Releases Results for Fourth Quarter and Full Year 2017

TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2017. Key highlights include:
  • Fourth quarter (Q4) 2017 Net Revenues of $5,901,488 increased by 18% versus Q4 2016
  • Full Year (FY) 2017 Net Revenues of $20,762,755 increased by 16% versus FY 2016
  • Q4 2017 Canadian Pharmaceutical Net Revenues of $4,937,297 increased by 12% versus Q4 2016 and International Pharmaceutical Net Revenues of $868,917 increased by 75% versus Q4 2016
  • FY 2017 Canadian Pharmaceutical Net Revenues of $16,856,703 increased by 12% versus FY 2016 and International Pharmaceutical Net Revenues of $2,476,902 increased by 60% versus FY 2016
  • Q4 2017 EBITDA1 of $1,961,159 increased by 23% versus Q4 2016
  • FY 2017 EBITDA1 of $6,910,977 increased by 17% versus FY 2016
  • Q4 2017 Net Income After Tax (NIAT) of $1,457,228 increased by 33% versus Q4 2016
  • FY 2017 NIAT of $5,206,277 increased by 21% versus FY 2016
  • Q4 2017 NIAT percentage to Net Revenues of 25% compares to 22% in Q4 2016
  • FY 2017 NIAT percentage to Net Revenues of 25% compares to 24% in FY 2016
  • Q4 2017 Fully Diluted EPS of $0.10 was 25% higher than Q4 2016 Fully Diluted EPS of $0.08
  • FY 2017 Fully Diluted EPS of $0.36 was 20% higher than FY 2016 Fully Diluted EPS of $0.30
  • As at December 31, 2017, the Company had cash, cash equivalents, and short term investments totalling $19,338,435 as compared to $13,739,286 as at December 31, 2016 – a 41% increase
  • Total Shareholders’ Equity increased by 33% from $16,726,716 at December 31, 2016 to $22,212,927 at December 31, 2017
  • Return on Equity for 2017 was 27% as compared to 30% for 2016
“BioSyent had a strong finish to 2017 with both our Canadian and International Pharmaceutical businesses posting record quarterly sales in Q4,” commented René Goehrum, President and CEO of BioSyent.  “Overall, 2017 was a year of continued organic growth, with our total sales of $20.8 million growing by 16% year-over-year.  While we continued to shepherd three new products through the regulatory approval process during the year, we maintained a net profit margin of 25%.  Once these new products are approved by Health Canada, they will add to the breadth and diversity of the Company’s product portfolio.  We look forward to the year ahead as we continue to grow our existing brands and strive to bring new, innovative pharmaceutical and healthcare products to market.”
The CEO’s presentation on the Q4 and FY 2017 Results is available at the following link: www.biosyent.com/q4-17/

The Company’s Audited Consolidated Financial Statements and Management's Discussion and Analysis for the years ended December 31, 2017 and 2016 will be posted on www.sedar.com on March 21, 2018.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 14,509,095 shares issued and outstanding.
BioSyent Inc.

Consolidated Statements of Comprehensive Income
In Canadian DollarsQ4 2017Q4 2016% Change 20172016% Change
Net Revenues 5,901,488 5,009,668 18%20,762,755 17,922,270 16%
Cost Of Goods Sold1,390,975 1,142,398 22%4,788,085 3,795,833 26%
Gross Profit 4,510,513 3,867,270 17%15,974,670 14,126,437 13%
Operating Expenses and Finance Income2,561,066 2,306,180 11%9,124,506 8,256,582 11%
Net Income Before Tax 1,949,447 1,561,090 25%6,850,164 5,869,855 17%
Tax (including Deferred Tax)492,219   466,268 6%1,643,887   1,560,350 5%
Net Income After Tax1,457,228 1,094,822 33%5,206,277 4,309,505 21%
Net Income After Tax % to Net Revenues 25%22%25%24%
EBITDA1,961,159 1,591,047 23%6,910,977 5,900,080 17%
EBITDA % to Net Revenues33%32%33%33%
  1. EBITDA –  is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
BioSyent Inc.
Consolidated Statements of Financial Position
AS AT December 31, 2017  December 31, 2016 % Change
ASSETS
Trade and other receivables$2,236,695 $1,941,177 15%
Inventory 908,825 1,560,050 -42%
Prepaid expenses and deposits147,326 269,704 -45%
Income tax recoverable71,924 -
Derivative asset- 32,025 -100%
Cash, cash equivalents and short-term investments19,338,435 13,739,286 41%
Current Assets22,703,205 17,542,242 29%
Equipment  290,926 291,331 0%
Intangible assets1,670,210 1,277,235 31%
Loans receivable393,860 -
Deferred tax asset46,647 137,375 -66%
TOTAL NON CURRENT ASSETS2,401,643 1,705,941 41%
TOTAL ASSETS$25,104,848 $19,248,183 30%
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities$2,615,594 $2,358,226 11%
Deferred tax liability276,327 163,241 69%
Long term debt- - 0%
Total Equity22,212,927 16,726,716 33%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$25,104,848 $19,248,183 30%

Comments

Post a Comment

Popular posts from this blog

Kyle Bass On Rehypothecation And Other Keynesian Endgame Scenarios

If readers have the sense there has been a deluge of Kyle Bass reading (and viewing) materials on Zero Hedge in the past two weeks, it is because there has been: and why not - after all, unlike all other cheap talking heads, and know-nothing pundits who merely need a suit to make an appearance on one of the TV's financial comedy channels, Kyle has been consistent in the most important thing - telling the truth. Today, he took his resurgent popularity to CNBC which always knows which way the winds blow, and told David Faber more or less everything that Zero Hedge readers know already about Europe's collapse, on why the ECB will print but only after a default, and about the inevitable global debt restructuring. There was a twist: as most regulars here know, the key topic of the past week, of December, and potentially of 2011, is the limitless "fractional Prime Broker lending" of assets-cum-liabilities (and when it comes to the realization that one's gold itself m
Read more

Jim Sinclair - CB’s Trying to Keep Gold from Rising Violently

Today legendary trader and investor Jim Sinclair told King World News that central banks are trying to keep the price of gold from rising violently. Sinclair also believes we are entering a period where currencies will lose their ability to function as money and instead will act more like casino chips, while gold ascends. Here is what Sinclair had to say about the ongoing financial crisis: “What needs to be understood by our listeners, Eric, is when a haircut takes place, what you give with one hand, you take with another. Now the problem becomes the problem of a bank’s asset having been reduced and the bank’s ability to function reduced and the bank’s abilities to positively pass tests of liquidity have been reduced. And the psychology of the stability of a system has been reduced.” Jim Sinclair continues: “When that takes place there has to be something on the other side called liquidity, which is injected into the banks to overcome the haircut reduction. Not only that, but
Read more